Physicians' Academy for Cardiovascular Education

DKD and CV risk: What is the potential of targeting GLP-1?

10' education - June 16, 2020 - Prof. Erik Stroes, MD - Amsterdam, The Netherlands

Video navigation menu

  • CVD risk in DKD patients 00:45
  • What drives residual CV risk in DKD? 03:25
  • Novel opportunities - anti-inflammatory strategies 05:31
  • Novel opportunities - targeting calcification 09:54
  • Mechanisms of CV benefit by GLP-1RAs 11:37

What is/are potential mechanism(s) for CV benefit by GLP-1RAs?

  • A. Improved glycemic control but unchanged lipid levels
  • B. GLP-1RA may upregulate expression of TNFα in the heart
  • C. Activation of GLP-1 on macrophages drives them into the active state (M1)
  • D. Dose-dependent weight reduction and lowering of blood pressure
Show the correct answer

Educational information

This lecture by prof. Erik Stroes was part of the EBAC-accredited symposium "Cardiorenal cross-talk in diabetes: The preventive challenge in DKD for GLP-1RA" held during ERA EDTA Virtual Congress 2020.


Prof. Erik Stroes, MD - Professor of Vascular Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.


Funding for this educational program was provided by an unrestricted educational grant from Novo Nordisk A/S.

View slides of the presentation Click here for the meeting report

Share this page with your colleagues and friends: